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Knee osteoarthritis (KOA)Abstract Aim of the work: The aim of the present work was to correlate between serum level of
leptin, matrix metalloproteinase-13 (MMP13), interleukin-1b (IL1b), tumour necrosis factor
(TNF-a), nitric oxide (NO) and functional impact in obese patients with knee osteoarthritis (KOA).
Patients and methods: The study included 84 obese patients suffering from primary KOA. The
knees were examined; pain assessed by visual analogue scale (VAS) and Lequesne’s index for func-
tional impact calculated. Serum leptin, MMP13, IL1b, TNF-a and NO were assessed.
Results: The mean age of the patients was 54.64 ± 7.7 years. They were 72 females and 12 males
(F:M= 6:1) with a mean BMI of 35.29 ± 4.8. Sixty patients had knee effusion which was bilateral in
54 (64.3%), unilateral in 6 (7.2%) while 24 (28.6%) did not have any effusion. Knee deformities were
present in 60 (71.4%) patients. Female patients were only signiﬁcantly higher than males regarding
Lequesne’s index (15.08 ± 4.4 vs 11 ± 3.4, p= 0.003). Patients with knee deformity had signiﬁcantly
higher VAS (9.12 ± 1.3 vs 6.96 ± 0.46, p= 0.001), IL1b (621.1 ± 98.8 vs 503.9 ± 74.6 pg/ml,
p= 0.001), TNF-a (115.4 ± 29.1 vs 87.4 ± 4.4 pg/ml, p= 0.001), NO (67.32 ± 5.7 vs
59.2 ± 2.2 lmol/L, p= 0.001), MMP13 (33.98 ± 2.24 vs 30.1 ± 1.7 ng/ml, p= 0.012) and leptin
(13.2 ± 1.6 vs 10.4 ± 0.6, p= 0.004) than those without. The VAS, Lequesne index, IL1b, TNF-a
NO, MMP13 and leptin were signiﬁcantly higher in patients with bilateral knee effusion
(p< 0.0001 for all) compared to those with unilateral effusion or without. Leptin signiﬁcantly corre-
lated with BMI, VAS, Lequesne’s index, IL1b, TNFa, NO and MMP13 (p< 0.0001 for all).
118 N.A. Hussein, G. ShararaConclusion: Leptin plays a key role in obese patients with knee OA. It signiﬁcantly correlates with
knee pain, functional impairment, inﬂammatory cytokines and cartilage degradation.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Knee osteoarthritis (KOA) is the most common type of arthri-
tis leading to pain and disability in the elderly population [1,2].
Obesity is a signiﬁcant risk factor for KOA and also increases
the risk of osteoarthritis (OA) in non-weight bearing joints
such as the hands [3]. This means that the mechanical factors
alone do not explain the cause effect relationship between obe-
sity and KOA [4]. In a previous study on Egyptian patients
with KOA it was found that synovial vascular endothelial
growth factor (VEGF) remarkably correlated with clinical
manifestations, functional impact, as well as radiological
changes [5]. In other studies, osteopontin served as a biochem-
ical marker of disease severity in KOA [6] and obesity
increased the risk of renal dysfunction [7] in Egyptian patients
with KOA. It has furthermore been reported that the measure-
ments of hyaluronic acid and serum cartilage oligomeric
matrix protein may be of diagnostic and prognostic value in
differentiating patients with early KOA. The combination with
other biochemical markers as well as with clinical and radio-
graphic data would most likely help to improve the clinical
assessment of KOA patients [8].
Recent studies suggest that systemic inﬂammatory media-
tors namely adipokines contribute to the increased risk of
osteoarthritis with obesity [9–11]. These adipokines mediate
synovial inﬂammation and up regulate cartilage matrix synthe-
sis and degradation [9,10]. One of those adipokines is leptin
which is a peptide hormone secreted primarily by adipocytes
[12,13]. It regulates body weight by centrally inhibiting food
intake and stimulating energy expenditure. Studies have shown
high serum and synovial levels of leptin in obese patients which
also correlated with percentage of body fat. This defect in lep-
tin action suggests that obesity may be associated with central
resistance to leptin [14,15]. Leptin modulates the degradative
functions of the chondrocytes through up-regulation of matrix
metalloproteases. Moreover, leptin was shown to enhance the
synthesis of proinﬂammatory mediators in human OA carti-
lage [15]. Thus, leptin may be a metabolic link between obesity
and OA [16].
The relationship between serum levels of leptin and the
severity of KOA in obese patients as reﬂected by the functional
impairment as well as laboratory parameters has to be more
clariﬁed. The aim of this study was to correlate between serum
level of leptin, matrix metalloproteinase-13 (MMP13),
interleukin-1b (IL1b), tumour necrosis factor-alpha (TNFa),
nitric oxide (NO) and functional impact in obese patients with
knee OA.
2. Patients and methods
This cross sectional study was conducted on 84 obese patients
(Body mass index BMIP 30 kg/m2) [17] suffering primary
knee OA according to the American College ofRheumatology (ACR) classiﬁcation criteria [18]. Patients that
did not receive any medication for treatment of the symptoms
of knee OA at least 4 weeks prior to obtaining their blood test
were enrolled in the study. Patients signed an informed consent
and the ethical approval was obtained from the research com-
mittee of our institution before initiation of the study. The
exclusion criteria were secondary OA due to any other causes
as rheumatologic diseases such as rheumatoid arthritis, any
clinical evidence of knee trauma or any orthopaedic diseases,
medical diseases such as diabetes mellitus, hypercholes-
terolemia or cardiovascular diseases.
The following data were recorded for all patients; medical,
occupational and drug history. The body mass index was cal-
culated [19] and a detailed knee examination was performed
including; alignment, presence of any deformity, bilaterality
of disease, tenderness and effusion. Visual analogue scale
(VAS) for knee pain was recorded [20]. Lequesne’s algofunc-
tional index was carried out [21].
Serum leptin was detected with enzyme-linked immuno-
sorbent assay (ELISA) (DRG International Inc., DRG
Leptin sandwich ELISA; EIA-2395); the following values
were observed: males 3.84 ± 1.79 ng/mL, females
7.36 ± 3.73 ng/ml. The MMP13 (Human Matrix
Metalloproteinase-13; MMP-13, ELISA Cat. No.:
RBMS2022R Biovendor – Laboratornı´, medicı´na a.s, Czech
republic), IL1b (Abcam’s Human Interleukin-1b ELISA kit
ab100562) TNF-a (RayBio Human TNF-alpha ELISA Kit
Cat#: ELH-TNFa RayBiotech, Inc.) and NO (Kit for
Quantitative Determination by Human Nitric oxide ELISA
Kit, CK-E30290, Glory Science) were measured using
ELISA. Normal serum Human MMP-13 levels ranged
between 0 and 9.7 ng/ml. Normal serum IL1b:
5.4 ± 3.9 pg/ml, ranging between 0 and 13.6 pg/ml. Normal
level of TNF-a was 11.2 ± 7.31 (0.0–32.5 pg/mL). Normal
NO ranged from 10 to 20 lmol/L.
2.1. Statistical analysis
Data were analysed using statistical package for social science
version 20(SPSS 20). Mean and standard deviation were used
to describe data distribution. T test was used for comparison
between 2 groups. Analysis of variance (ANOVA) was used
for comparison between more than 2 groups. Pearson correla-
tion was used to study the association between two parame-
ters. The level of signiﬁcance was 0.05.
3. Results
Eighty-four obese patients suffering from primary knee
osteoarthritis were included in the study. Seventy-two
(85.7%) were females and 12 (14.3%) males. The mean age
was 54.6 ± 7.7 (41–72 years). The mean BMI was 35.3 ± 4.8
(30–50.2). Sixty patients (71.4%) had knee deformity.
Correlation between serum levels and functional impact in obese patients with KOA 119Fifty-four patients (64.3%) had bilateral knee effusion, while 6
(7.1%) had unilateral knee effusion and the remaining 24
(28.6%) had no effusion. Table 1 shows the visual analogue
scale of knee pain, Lequesne index and studied laboratory
parameters in obese KOA patients.
Leptin was signiﬁcantly correlated with BMI (r= .394,
p= 0.0001), VAS (r= 0.714, p= 0.0001), and Lequesne
index (r= 0.714, p= .0001). In addition leptin signiﬁcantly
correlated with all tested laboratory variables as shown in
Fig. 1 (p= 0.0001 for all). Table 2 documents that those with
bilateral knee effusion had signiﬁcantly higher BMI, VAS,
Lequesne score and all tested laboratory variables inTable 1 The visual analogue scale of knee pain, Lequesne
index and studied laboratory parameters in obese knee
osteoarthritis patients (n= 84).
Parameter Obese knee osteoarthritis patients (n= 84)
Mean ± SD Range (Min–Max)
VAS knee pain 8.5 ± 1.5 (5–10)
Lequesne index 14.5 ± 4.5 (5.5–20.5)
IL1b (pg/ml) 587.6 ± 106.4 (314–780)
TNF-a (pg/ml) 107.4 ± 27.8 (76–177)
NO (lmol/L) 64.99 ± 6.2 (50.1–77.7)
MMP13 (ng/ml) 32.9 ± 2.7 (27.8–37.6)
Leptin (ng/ml) 12.4 ± 1.9 (9.6–16.1)
VAS: visual analogue scale, IL1: interleukin-1, TNF: tumour
necrosis factor, NO: nitric oxide, MMP: matrix metallo-proteinase.
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Figure 1 Correlation between serum leptin and MMP13 (upper left
obese knee OA patients.comparison with patients with no effusion or unilateral effu-
sion. There was no signiﬁcant difference between those with
unilateral effusion and those without effusion regarding all
variables. Table 3 shows that patients with knee deformity
had signiﬁcantly higher VAS, cytokines, NO, MMP13 and lep-
tin than those without. Table 4 shows a comparison of the
studied variables according to gender. Only the Lequesne
index was signiﬁcantly higher in females.
4. Discussion
This study was conducted on 84 obese patients with KOA to
assess the role of leptin and its correlation with clinical and
functional derangement, cytokine production and cartilage
degradation. The current study showed a signiﬁcant correla-
tion between serum leptin and BMI. Revising literature, serum
leptin was elevated in obese persons and correlated with the
percent of body fat [13,14,22], also leptin concentration
decreased after weight loss [22]. High serum and synovial lep-
tin in obese patients with OA were thought to control local
inﬂammatory processes [23]. As obesity itself without leptin
does not predispose to OA [24], it was suggested that elevated
leptin might explain the metabolic role of obesity in knee OA
[25,26].
The present study demonstrated a signiﬁcant correlation
between leptin and cytokines IL1b, TNFa. Gandhi et al. [27]
found a signiﬁcant correlation between serum and synovial
level of leptin and IL1b and high serum level of TNFa and
MMP13 among patients undergoing total knee replacement0
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), IL1b (upper right), TNF-a (lower left) and NO (lower right) in
Table 2 Relation of the studied variables according to knee effusion in obese KOA patients (n= 84).
Variable Knee eﬀusion p
No eﬀusion Unilateral Bilateral
VAS 6.6 ± 0.7 7.5 ± 0.5 9.4 ± 0.8 <0.0001
Lequesne index 12.2 ± 5.8 9.3 ± 0.8 16.1 ± 2.9 <0.0001
BMI 34.4 ± 3.4 35.2 ± 4.1 40.1 ± 11.1 0.032
IL1b (pg/ml) 478.7 ± 96.2 534.7 ± 44.9 641.9 ± 69.5 <0.0001
TNF-a (pg/ml) 86.1 ± 5.2 89 ± 6.6 118.9 ± 28.5 <0.0001
NO (lmol/L) 57.9 ± 3.4 61.3 ± 4.1 68.6 ± 3.95 <0.0001
MMP13 (ng/ml) 29.8 ± 1.6 30.8 ± 2.02 34.5 ± 1.7 <0.0001
Leptin (ng/ml) 10.3 ± 0.5 11.1 ± 1.3 13.5 ± 1.4 <0.0001
KOA: knee osteoarthritis, VAS: visual analogue scale, BMI: body mass index, IL1: interleukin-1, TNF: tumour necrosis factor, NO: nitric
oxide, MMP: matrix metallo-proteinase. Bold values = signiﬁcant at p< 0.05.
Table 3 Comparison between different studied variables
according to the presence and absence of knee deformity in
obese patients with KOA (n= 84).
Variable Knee deformity t p
Yes (n= 60) No (n= 24)
VAS 9.1 ± 1.3 6.96 ± 0.5 5.99 <0.001
Lequesne index 15.03 ± 3.9 13.2 ± 5.6 3.1 0.09
BMI 35.6 ± 5.1 34.5 ± 3.95 0.9 0.34
IL1b (pg/ml) 621.1 ± 98.8 503.9 ± 74.6 7.4 <0.001
TNF-a (pg/ml) 115.4 ± 29.1 87.4 ± 4.4 4.96 <0.001
NO (lmol/L) 67.3 ± 5.7 59.2 ± 2.2 6.01 <0.001
MMP13 (ng/ml) 33.98 ± 2.2 30.1 ± 1.7 5.1 0.01
Leptin (ng/ml) 13.2 ± 1.6 10.4 ± 0.6 3.8 0.004
KOA: Knee osteoarthritis, VAS: Visual analogue scale, BMI: Body
mass index, IL1: Interleukin-1, TNF: Tumour necrosis factor, NO:
nitric oxide, MMP: matrix metallo-proteinase. Bold values =
signiﬁcant at p< 0.05.
Table 4 Comparison between different studied variables
according to gender in obese patients with KOA (n= 84).
Variable Gender t p
Females (72) Males (12)
VAS 8.5 ± 1.5 8.8 ± 1.4 0.4 0.5
Lequesne index 15.1 ± 4.4 11 ± 3.4 9.4 0.003
BMI 35.5.6 ± 5.2 34.2 ± 1.5 0.7 0.4
IL1b (pg/ml) 581.8 ± 109.4 622.2 ± 81.8 1.5 0.2
TNF-a (pg/ml) 108.02 ± 29.4 103.8 ± 14.5 0.2 0.6
NO (lmol/L) 64.9 ± 6.5 65.3 ± 4.3 0.03 0.9
MMP13 (ng/ml) 32.8 ± 2.7 33.5 ± 2.8 0.8 0.4
Leptin (ng/ml) 12.4 ± 1.97 12.3 ± 1.4 0.03 0.9
KOA: knee osteoarthritis, VAS: visual analogue scale, BMI: body
mass index, IL1: interleukin-1, TNF: tumour necrosis factor, NO:
nitric oxide, MMP: matrix metallo-proteinase. Bold values =
signiﬁcant at p< 0.05.
120 N.A. Hussein, G. Sharara[27]. In the current study, leptin was also signiﬁcantly corre-
lated with NO. Previously, this was also reported [28].
The present study documented a signiﬁcant correlation
between serum leptin and MMP13 level. This is in agreement
with previous studies where leptin was found to increase
production of metalloproteinases thus enhancing cartilage
degradation [15,29–31]. Leptin modulates the degradative
functions of the chondrocytes through up-regulation of matrix
metalloproteases (MMP)-9 and -13 and IL-1b. Moreover, lep-
tin was shown to enhance the synthesis of proinﬂammatory
mediators in OA cartilage and to potentiate the IL-1-
mediated production of NO, which is known to contribute
to cartilage matrix loss [15].
The role of cytokines in the pathophysiology of OA is well
documented. Cytokines such as IL1b and TNFa produced by
activated synoviocytes, mononuclear cells or by articular carti-
lage itself signiﬁcantly up regulate metalloproteinases [32].
Also cytokines synergistically increase NO which is involved
in the inﬂammatory process of OA [33].
As shown in this study, leptin had a linear correlation with
BMI which reﬂects obesity. Also it had a signiﬁcant correlation
with all tested cytokines as well as MMP13. Thus leptin might
be the initiating factor for the cascade of inﬂammation and
cartilage degradation in obese KOA patients.This study showed a signiﬁcant correlation between knee
pains documented by VAS and serum leptin. Bas et al. [34]
and Perruccio et al. [35] found an association between pain
severity and serum adipokine including leptin in knee and
hip OA. Lu¨bbeke et al. concluded that high synovial leptin is
associated with severe preoperative pain in obese women with
hip and knee OA [36].
The present study showed a signiﬁcant correlation between
serum leptin and Lequesne index which denotes worse func-
tional status of the patients. No previous literature discussed
the relation of serum leptin and functional status of obese
OA patients as worse function denotes usually a more
advanced and severe disease. The positive relation between
the severity of knee OA and serum leptin was documented
before [37].
This study showed that patients with bilateral knee effusion
had signiﬁcantly higher BMI, worse clinical manifestation
measured by knee pain and Lequesne index as well as higher
cytokines, MMP13 and leptin as compared with patients with-
out or with only unilateral effusion. Knee effusion is a mani-
festation of ongoing synovitis and inﬂammation [38]. So this
result is an additional proof that knee inﬂammation is propor-
tionate to the degree of obesity, hence leptin and all the follow-
ing cascade of inﬂammation.
Correlation between serum levels and functional impact in obese patients with KOA 121The current study proved that patients with knee deformity
had signiﬁcantly higher knee pain, cytokines, NO, MMP13
and leptin than those without. Knee deformity usually occurs
in advanced knee OA [39]. This also denotes that those with
knee deformity i.e. advanced OA had higher leptin and cytoki-
nes and cartilage degradation. In a previous study, serum lep-
tin signiﬁcantly correlated with the severity of knee OA [37].
In the present study, we did not ﬁnd signiﬁcant difference
between male and female regarding all tested variables except
for signiﬁcantly higher Lequesne in females. Less number of
male patients may be the cause, but the patients were recruited
randomly and sequentially.
A previous study detected higher serum leptin in women
compared to men [40]. One study suggested that the higher
serum leptin in women might partially account for gender dis-
parity of KOA [26].
Since the aim of the study was originally mere correlation,
control group was not included, but as the clinical and labora-
tory results prove a strong relation between leptin and severity
of KOA in obese patients, additional longitudinal studies on a
larger population and taking into consideration a control
group of non obese KOA patients are encouraged to verify
our results and performing a regression analysis could further
conﬁrm the role of leptin in this group of patients.
In conclusion, leptin is proportionate with the degree of
obesity and is extremely related to the degree of inﬂammation
and cartilage degradation in obese patients with knee
osteoarthritis, hence the severity of KOA.Conﬂict of interest
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